H3N2 Infection Pipeline Review, H2 2015
Summary
Global Markets Directs, H3N2 Infection Pipeline Review, H2 2015, provides an overview of the H3N2 Infections therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
H3N2 Infection Overview 9
Therapeutics Development 10
Pipeline Products for H3N2 Infection - Overview 10
Pipeline Products for H3N2 Infection - Comparative Analysis 11
H3N2 Infection - Therapeutics under Development by Companies 12
H3N2 Infection - Therapeutics under Investigation by Universities/Institutes 13
H3N2 Infection - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
H3N2 Infection - Products under Development by Companies 17
H3N2 Infection - Products under Investigation by Universities/Institutes 18
H3N2 Infection - Companies Involved in Therapeutics Development 19
Aphios Corporation 19
Crucell N.V. 20
CSL Limited 21
ILiAD Biotechnologies, LLC 22
Inovio Pharmaceuticals, Inc. 23
Johnson & Johnson 24
Medicago Inc. 25
Mucosis B.V. 26
NanoViricides, Inc. 27
REPLICor Inc. 28
Sarepta Therapeutics, Inc. 29
Takeda Pharmaceutical Company Limited 30
H3N2 Infection - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
APP-0205 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
APP-309 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Aspidasept - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
C-05 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CR-9114 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Gamma-Flu - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ID-38 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
influenza [strain A/H3N2] vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
influenza [Strains H1N1, H3N2, influenza B] (quadrivalent) virus like particle vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
influenza vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
JNJ-872 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Monoclonal Antibody for Influenza A Infections - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
NVINF-1 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
NVINF-2 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pertussis [strain BPZE1] vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
PNSIA-28 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
radavirsen - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
REP-9 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for RSV and Influenza A Infections - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
H3N2 Infection - Recent Pipeline Updates 69
H3N2 Infection - Dormant Projects 79
H3N2 Infection - Product Development Milestones 80
Featured News & Press Releases 80
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 80
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza 80
Jul 26, 2012: Novartis Begins Shipment Of Fluvirin Seasonal Influenza Vaccine In US For 2012-2013 Influenza Season 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83
List of Tables
Number of Products under Development for H3N2 Infection, H2 2015 10
Number of Products under Development for H3N2 Infection - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
H3N2 Infection - Pipeline by Aphios Corporation, H2 2015 19
H3N2 Infection - Pipeline by Crucell N.V., H2 2015 20
H3N2 Infection - Pipeline by CSL Limited, H2 2015 21
H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H2 2015 22
H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 23
H3N2 Infection - Pipeline by Johnson & Johnson, H2 2015 24
H3N2 Infection - Pipeline by Medicago Inc., H2 2015 25
H3N2 Infection - Pipeline by Mucosis B.V., H2 2015 26
H3N2 Infection - Pipeline by NanoViricides, Inc., H2 2015 27
H3N2 Infection - Pipeline by REPLICor Inc., H2 2015 28
H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H2 2015 29
H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 30
Assessment by Monotherapy Products, H2 2015 31
Assessment by Combination Products, H2 2015 32
Number of Products by Stage and Target, H2 2015 34
Number of Products by Stage and Mechanism of Action, H2 2015 36
Number of Products by Stage and Route of Administration, H2 2015 38
Number of Products by Stage and Molecule Type, H2 2015 40
H3N2 Infection Therapeutics - Recent Pipeline Updates, H2 2015 69
H3N2 Infection - Dormant Projects, H2 2015 79
List of Figures
Number of Products under Development for H3N2 Infection, H2 2015 10
Number of Products under Development for H3N2 Infection - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Products, H2 2015 16
Assessment by Monotherapy Products, H2 2015 31
Assessment by Combination Products, H2 2015 32
Number of Products by Top 10 Targets, H2 2015 33
Number of Products by Stage and Top 10 Targets, H2 2015 33
Number of Products by Top 10 Mechanism of Actions, H2 2015 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 35
Number of Products by Top 10 Routes of Administration, H2 2015 37
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 37
Number of Products by Top 10 Molecule Types, H2 2015 39
Number of Products by Stage and Top 10 Molecule Types, H2 2015 39
